Sarah Pett | |
---|---|
Alma mater | University of Edinburgh |
Scientific career | |
Fields | Immunopathology |
Institutions |
University of New South Wales University College London |
Sarah L. Pett is a Professor of Infectious Diseases at University College London. Pett is interested in the immunopathology of infections and the development of optimised treatment pathways for infections. During the COVID-19 pandemic, Pett led a clinical trial that investigated the efficacy of remdesivir as a treatment for coronavirus disease. [1]
In 2000 Pett joined the Kirby Institute in New South Wales, where she led international randomized controlled trials. [2] [3] In 2013 Pett joined the Medical Research Council Clinical Trials Unit at University College London. She was promoted to the Chair of the Infectious Diseases theme in 2016. [4]
During the COVID-19 pandemic Pett led the Adaptive COVID-19 Treatment Trial (ACTT-EU/UK), a clinical trial into the efficacy of remdesivir as a treatment from coronavirus disease. Adult inpatients were given remdesivir or a placebo through a drip for up to ten days of their stay in hospital. [5] Pett showed that patients treated with remdesivir recovered 31% faster than those who did not receive treatment. [5]
She has also been involved in research on the neurological complications from COVID-19 and the co-morbid conditions that it may induce. [6]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link){{
cite journal}}
: CS1 maint: multiple names: authors list (
link)Sarah Pett | |
---|---|
Alma mater | University of Edinburgh |
Scientific career | |
Fields | Immunopathology |
Institutions |
University of New South Wales University College London |
Sarah L. Pett is a Professor of Infectious Diseases at University College London. Pett is interested in the immunopathology of infections and the development of optimised treatment pathways for infections. During the COVID-19 pandemic, Pett led a clinical trial that investigated the efficacy of remdesivir as a treatment for coronavirus disease. [1]
In 2000 Pett joined the Kirby Institute in New South Wales, where she led international randomized controlled trials. [2] [3] In 2013 Pett joined the Medical Research Council Clinical Trials Unit at University College London. She was promoted to the Chair of the Infectious Diseases theme in 2016. [4]
During the COVID-19 pandemic Pett led the Adaptive COVID-19 Treatment Trial (ACTT-EU/UK), a clinical trial into the efficacy of remdesivir as a treatment from coronavirus disease. Adult inpatients were given remdesivir or a placebo through a drip for up to ten days of their stay in hospital. [5] Pett showed that patients treated with remdesivir recovered 31% faster than those who did not receive treatment. [5]
She has also been involved in research on the neurological complications from COVID-19 and the co-morbid conditions that it may induce. [6]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link){{
cite journal}}
: CS1 maint: multiple names: authors list (
link)